Dublin, April 11, 2023 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Size, Share & Trends Analysis Report by Drug Class, by Disease (Dry Eye, Glaucoma), by Dosage Form, by Route of Administration, by Product Type (Prescription, OTC), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
The global ophthalmic drugs market size is expected to reach USD 65.6 billion by 2030, garnering a CAGR of 7.7% from 2022 to 2030.
Companies Mentioned
- Alcon
- Novartis AG
- Johnson & Johnson Services, Inc.
- Bausch Health
- Merck & Co. Inc.
- Regeneron Pharmaceuticals, Inc.
- Coherus Biosciences, Inc.
- Allergan
- Pfizer, Inc.
- Bayer AG
- Santen Pharmaceuticals Co. Ltd.
- Genetech, Inc.
The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs.
According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.
Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth.
Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure.
For instance, as per AMERICA's HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.
Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.
Ophthalmic Drugs Market Report Highlights
- Anti-VEGF agents segment held the largest share in 2021 owing to their rising demand and lesser adverse effects
- Retinal disorders held the largest market share in 2021 owing to the rising prevalence of age-related macular degeneration and diabetic retinopathy
- The topical route of administration dominated the market in 2021 owing to factors such as the benefits of the topical route as it delivers the drug to the targeted site and ease of use
- The eye drops segment is expected to hold the largest share in 2021 owing to rising demand for eye drops, high patient compliance, and availability of OTC products
- Asia Pacific is expected to exhibit the fastest growth over the forecast period due to advancements in healthcare infrastructure, increasing demand for eye products, and a large patient pool
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $35.8 Billion |
| Forecasted Market Value (USD) by 2030 | $65.6 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1 Ophthalmic Drugs Market: Methodology and Scope
Chapter 2 Ophthalmic Drugs Market: Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Ophthalmic Drugs Market: Industry Outlook
3.1 Market Lineage Outlook
3.2 Regulatory Framework
3.3 Patent Expiry Analysis
3.4 Pipeline Analysis
3.4.1 Pipeline Analysis, By Phase (Funder Type- Industry)
3.4.2 Pipeline Analysis, By Phase (Funder Type- All Others)
3.5 Cost Structure Analysis
3.6 Market Dynamics
3.6.1 Market Drivers Analysis
3.6.1.1 Increasing Disease Prevalence
3.6.1.2 Strong Developmental Pipeline
3.6.1.3 Advancements In Drug Delivery
3.6.1.4 Promising Investment Scenario
3.6.2 Market Restraint Analysis
3.6.2.1 Patent Expiry Of Blockbuster Drugs
3.7 Penetration & Growth Prospect Mapping
3.8 Ophthalmic Drugs: Market Analysis Tools
3.9 Primary Research Analysis
Chapter 4 Ophthalmic Drugs Market: Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)
4.1 Definition and Scope
4.2 Drug Class Market Share Analysis, 2021 & 2030
4.3 Segment Dashboard
4.4 Global Ophthalmic Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
4.5 Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
Chapter 5 Ophthalmic Drugs Market: Segment Analysis, By Disease, 2018 - 2030 (USD Million)
5.1 Definition and Scope
5.2 Disease Market Share Analysis, 2021 & 2030
5.3 Segment Dashboard
5.4 Global Ophthalmic Drugs Market, by Disease, 2018 - 2030 (USD Million)
5.5 Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
Chapter 6 Ophthalmic Drugs Market: Segment Analysis, By Route of Administration, 2018 - 2030 (USD Million)
6.1 Definition and Scope
6.2 Route of Administration Market Share Analysis, 2021 & 2030
6.3 Segment Dashboard
6.4 Global Ophthalmic Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
6.5 Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
Chapter 7 Ophthalmic Drugs Market: Segment Analysis, By Dosage Form, 2018 - 2030 (USD Million)
7.1 Definition and Scope
7.2 Dosage Form Market Share Analysis, 2021 & 2030
7.3 Segment Dashboard
7.4 Global Ophthalmic Drugs Market, by Dosage Form, 2018 - 2030 (USD Million)
7.5 Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
Chapter 8 Ophthalmic Drugs Market: Segment Analysis, By Product Type, 2018 - 2030 (USD Million)
8.1 Definition and Scope
8.2 Product Type Market Share Analysis, 2021 & 2030
8.3 Segment Dashboard
8.4 Global Ophthalmic Drugs Market, by Product Type, 2018 - 2030 (USD Million)
8.5 Market Size & Forecasts and Trend Analyses, 2018 - 2030 (USD Million)
Chapter 9 Ophthalmic Drugs Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)
Chapter 10 Ophthalmic Drugs Market: Competitive Analysis
For more information about this report visit https://www.researchandmarkets.com/r/bbhxtv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
